Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.58
DCTH's Cash to Debt is ranked lower than
69% of the 790 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.44 vs. DCTH: 0.58 )
Ranked among companies with meaningful Cash to Debt only.
DCTH' s Cash to Debt Range Over the Past 10 Years
Min: 0.58  Med: No Debt Max: No Debt
Current: 0.58
Equity to Asset 0.12
DCTH's Equity to Asset is ranked lower than
95% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. DCTH: 0.12 )
Ranked among companies with meaningful Equity to Asset only.
DCTH' s Equity to Asset Range Over the Past 10 Years
Min: 0.12  Med: 0.75 Max: 0.84
Current: 0.12
0.12
0.84
F-Score: 2
Z-Score: -10.84
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -927.92
DCTH's Operating margin (%) is ranked lower than
93% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.64 vs. DCTH: -927.92 )
Ranked among companies with meaningful Operating margin (%) only.
DCTH' s Operating margin (%) Range Over the Past 10 Years
Min: -15569.65  Med: -2992.71 Max: -870.64
Current: -927.92
-15569.65
-870.64
Net-margin (%) -830.66
DCTH's Net-margin (%) is ranked lower than
93% of the 737 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.21 vs. DCTH: -830.66 )
Ranked among companies with meaningful Net-margin (%) only.
DCTH' s Net-margin (%) Range Over the Past 10 Years
Min: -14990.75  Med: -2732.2 Max: -830.66
Current: -830.66
-14990.75
-830.66
ROE (%) -182.73
DCTH's ROE (%) is ranked lower than
97% of the 763 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.92 vs. DCTH: -182.73 )
Ranked among companies with meaningful ROE (%) only.
DCTH' s ROE (%) Range Over the Past 10 Years
Min: -224.96  Med: -110.94 Max: -29.88
Current: -182.73
-224.96
-29.88
ROA (%) -57.76
DCTH's ROA (%) is ranked lower than
91% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. DCTH: -57.76 )
Ranked among companies with meaningful ROA (%) only.
DCTH' s ROA (%) Range Over the Past 10 Years
Min: -157.86  Med: -82.11 Max: -27.27
Current: -57.76
-157.86
-27.27
ROC (Joel Greenblatt) (%) -1331.53
DCTH's ROC (Joel Greenblatt) (%) is ranked lower than
91% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.01 vs. DCTH: -1331.53 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
DCTH' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -194983.33  Med: -1125.65 Max: -161.78
Current: -1331.53
-194983.33
-161.78
Revenue Growth (3Y)(%) 6.10
DCTH's Revenue Growth (3Y)(%) is ranked higher than
51% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.50 vs. DCTH: 6.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
DCTH' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 6.1
Current: 6.1
0
6.1
EBITDA Growth (3Y)(%) -60.20
DCTH's EBITDA Growth (3Y)(%) is ranked lower than
98% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.50 vs. DCTH: -60.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
DCTH' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -60.2  Med: -5.2 Max: 56.4
Current: -60.2
-60.2
56.4
EPS Growth (3Y)(%) -59.30
DCTH's EPS Growth (3Y)(%) is ranked lower than
97% of the 539 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.30 vs. DCTH: -59.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
DCTH' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -59.3  Med: -16.4 Max: 95.7
Current: -59.3
-59.3
95.7
GuruFocus has detected 3 Warning Signs with Delcath Systems Inc $DCTH.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» DCTH's 10-Y Financials

Financials (Next Earnings Date: 2017-03-21)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

DCTH Guru Trades in Q1 2016

Jim Simons 682,498 sh (+5.32%)
» More
Q2 2016

DCTH Guru Trades in Q2 2016

Jim Simons 754,998 sh (+10.62%)
» More
Q3 2016

DCTH Guru Trades in Q3 2016

Jim Simons 59,914 sh (+26.97%)
» More
Q4 2016

DCTH Guru Trades in Q4 2016

Jim Simons 160,128 sh (+167.26%)
» More
» Details

Insider Trades

Latest Guru Trades with DCTH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325411    SIC: 3841
Compare:OTCPK:PVCT, OTCPK:YBAO, OTCPK:ULUR, OTCPK:ICCLF, OTCPK:NRXCF, OTCPK:ADMD, OTCPK:RSPI, OTCPK:PTLF, AMEX:IGC, OTCPK:PCYN, OTCPK:YRLLF, OTCPK:PUFXF, OTCPK:MJTK, NAS:ACUR, OTCPK:AQSZF, OTCPK:RLMD, OTCPK:PARNF, OTCPK:EMMBF, NAS:MYOS, OTCPK:CYIG » details
Traded in other countries:DV32.Germany,
Delcath Systems Inc is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver.

Delcath Systems Inc is a Delaware corporation, incorporated on August 5, 1988. The Company is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. It is a specialty pharmaceutical and medical device company developing its proprietary product-Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). In Europe, its proprietary system to deliver and filter melphalan hydrochloride is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). Its primary focus is on the execution of its clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver), and certain other cancers that are metastatic to the liver. The Company currently operates in one business segment, which is the development and commercialization of CHEMOSAT/Melphalan/HDS. Its competitors include Covidian, Biocompatibles, Merit, CeleNova, SirTex, AngioDynamics, and many others. The Company currently holds eight U.S. utility patents, one U.S. design patent, six pending U.S. utility patent applications (one of which has been allowed), four issued foreign counterpart utility patents, six issued foreign counterpart design patents, and eight pending foreign counterpart patent applications (one of which has been allowed). The Company's products are subject to extensive and rigorous government regulation by foreign regulatory agencies and the FDA.

Ratios

vs
industry
vs
history
P/B 0.07
DCTH's P/B is ranked higher than
100% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.02 vs. DCTH: 0.07 )
Ranked among companies with meaningful P/B only.
DCTH' s P/B Range Over the Past 10 Years
Min: 0.05  Med: 1.04 Max: 6.25
Current: 0.07
0.05
6.25
P/S 0.14
DCTH's P/S is ranked higher than
99% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.06 vs. DCTH: 0.14 )
Ranked among companies with meaningful P/S only.
DCTH' s P/S Range Over the Past 10 Years
Min: 0.12  Med: 14.23 Max: 1044.69
Current: 0.14
0.12
1044.69
Current Ratio 1.15
DCTH's Current Ratio is ranked lower than
82% of the 726 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.49 vs. DCTH: 1.15 )
Ranked among companies with meaningful Current Ratio only.
DCTH' s Current Ratio Range Over the Past 10 Years
Min: 0.58  Med: 6.1 Max: 67.13
Current: 1.15
0.58
67.13
Quick Ratio 1.13
DCTH's Quick Ratio is ranked lower than
71% of the 725 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. DCTH: 1.13 )
Ranked among companies with meaningful Quick Ratio only.
DCTH' s Quick Ratio Range Over the Past 10 Years
Min: 0.58  Med: 5.9 Max: 67.13
Current: 1.13
0.58
67.13
Days Inventory 513.31
DCTH's Days Inventory is ranked lower than
97% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.19 vs. DCTH: 513.31 )
Ranked among companies with meaningful Days Inventory only.
DCTH' s Days Inventory Range Over the Past 10 Years
Min: 436.89  Med: 693.6 Max: 5170.83
Current: 513.31
436.89
5170.83
Days Sales Outstanding 71.13
DCTH's Days Sales Outstanding is ranked higher than
53% of the 628 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.32 vs. DCTH: 71.13 )
Ranked among companies with meaningful Days Sales Outstanding only.
DCTH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 57.87  Med: 105.66 Max: 161.25
Current: 71.13
57.87
161.25
Days Payable 139.85
DCTH's Days Payable is ranked higher than
82% of the 574 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.12 vs. DCTH: 139.85 )
Ranked among companies with meaningful Days Payable only.
DCTH' s Days Payable Range Over the Past 10 Years
Min: 139.85  Med: 698.02 Max: 8788.08
Current: 139.85
139.85
8788.08

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -65.50
DCTH's 3-Year Average Share Buyback Ratio is ranked lower than
95% of the 436 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.40 vs. DCTH: -65.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DCTH' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -65.5  Med: -26 Max: -12.6
Current: -65.5
-65.5
-12.6

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 0.06
DCTH's Price/Tangible Book is ranked higher than
100% of the 747 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.65 vs. DCTH: 0.06 )
Ranked among companies with meaningful Price/Tangible Book only.
DCTH' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.05  Med: 4.8 Max: 42.99
Current: 0.06
0.05
42.99
Price/Median PS Value 0.01
DCTH's Price/Median PS Value is ranked higher than
100% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. DCTH: 0.01 )
Ranked among companies with meaningful Price/Median PS Value only.
DCTH' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.01  Med: 1.25 Max: 59.16
Current: 0.01
0.01
59.16
Earnings Yield (Greenblatt) (%) -247.45
DCTH's Earnings Yield (Greenblatt) (%) is ranked lower than
99% of the 835 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. DCTH: -247.45 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DCTH' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -277.94  Med: 273.1 Max: 190327.2
Current: -247.45
-277.94
190327.2

More Statistics

Revenue (TTM) (Mil) $1.76
EPS (TTM) $ -10.16
Beta2.05
Short Percentage of Float50.76%
52-Week Range $0.13 - 6.85
Shares Outstanding (Mil)31.80

Analyst Estimate

Dec16
Revenue (Mil $)
EPS ($) 0.01
EPS w/o NRI ($) 0.01
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for DCTH

Headlines

Articles On GuruFocus.com
Five NCAV Companies for Value Investors – August 2015 Aug 04 2015 
Weekly CFO Buys Highlight: BWEN, EMC, INO, DCTH, ACCO Jun 11 2012 
Delcath Systems Inc. Reports Operating Results (10-Q) Oct 23 2009 

More From Other Websites
DELCATH SYSTEMS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Feb 22 2017
8:02 am Delcath announces publication of a review of investigational PHP with Melphalan/HDS in the... Feb 22 2017
Published Review Shows Delcath Investigational PHP Doubles Overall Survival Over Other Targeted... Feb 22 2017
Analysis From Two Institutions Shows Strong Tumor Response, Overall Survival Potential of Delcath... Feb 21 2017
DELCATH SYSTEMS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial... Feb 15 2017
Delcath Systems to Present at the 2nd Annual Disruptive Growth & Healthcare Conference Feb 06 2017
DELCATH SYSTEMS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 30 2017
DELCATH SYSTEMS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events Jan 26 2017
Delcath Systems To Present At The NobleCon13 - Noble Capital Markets' Thirteenth Annual Investor... Jan 23 2017
New Outcomes Data Using Delcath's Melphalan/HDS To Treat Unresectable Metastatic Ocular Melanoma To... Jan 18 2017
Delcath Announces Ongoing Patient Treatment And Data Collection In Intrahepatic Cholangiocarcinoma... Jan 12 2017
DryShips, Merrimack Tumble into Friday’s 52-Week Low Club Jan 06 2017
Delcath Systems to Present at the 9th Annual LD Micro Main Event Nov 30 2016
DELCATH SYSTEMS, INC. Financials Nov 18 2016
Delcath Systems, Inc. :DCTH-US: Earnings Analysis: Q3, 2016 By the Numbers : November 14, 2016 Nov 14 2016
Delcath Announces Third Quarter Financial Results Nov 11 2016
Delcath Announces Third Quarter Financial Results Nov 11 2016
DELCATH SYSTEMS, INC. Files SEC form 10-Q, Quarterly Report Nov 10 2016
DELCATH SYSTEMS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 18 2016
Delcath Issues Letter to Stockholders Oct 18 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)